Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population

What Was Tested

The paper reports a study of CGRP (Calcitonin Gene-Related Peptide) in the context of migraine, published as an observational study.

Objective variables included the DHI score and explanatory variables included demographic data, balance test results, head-up tilt (HUT) test results, vestibular test results and questionnaire survey results.

Analysis of variance was used to assess the treatment effects of anti-CGRP mAbs, and multivariate regression analysis was performed to identify mAb responders.

Why It Was Studied

Migraine and dizziness often coexist, with vestibular migraine (VM) presenting with vestibular symptoms and headaches.

Calcitonin gene-related peptide (CGRP) may be involved in motion-induced symptoms; however, studies on the use of anti-CGRP monoclonal antibodies (mAbs) for the treatment of VM have yielded conflicting results.

Who Took Part

The abstract describes 2023, patients taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

Clinical questionnaires and equilibrium tests were administered, with primary outcomes including changes in Dizziness Handicap Inventory (DHI) scores compared with baseline values.

What Was Measured

PubMed files the paper under topics including Antibodies, Monoclonal, Calcitonin Gene-Related Peptide, Cohort Studies, Dizziness, Japan, Migraine Disorders and Surveys and Questionnaires.

What This Means in Plain Language

This is an observational study of CGRP (Calcitonin Gene-Related Peptide) in 2023, patients in people with migraine.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (CNS drugs), a journal based in New Zealand.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.